Skip to main content
Fig. 5 | Clinical Proteomics

Fig. 5

From: Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization

Fig. 5

Antibody-based confirmation of the selected upregulated cell-surface IMPs. (A) Western blots of 22 tumor samples and 2 controls (NAM pools). (B) Results of densitometric analyses of the blots. To normalize the signal intensity between the 2 blots, either sample 22 or sample 4 (in case of CD146 and ANO1) are present on both membranes and used as an internal standard. Due to the heterogeneity of tumors, standard loading “housekeeping“ proteins, such as glyceraldehyde-3-phosphate (GAPDH), tubulin, and actin, could not be used, as their antibody-detected levels varied significantly among the individual samples. Therefore, we used a Coomassie Brilliant Blue-stained gel as a loading control. ANO1, anocatamin 1 (TMEM16A); ACE, angiotensin-converting enzyme; ATP8A1, phospholipid-transporting ATPase IA; SLC7A1, high-affinity cationic amino acid transporter 1

Back to article page

Clinical Proteomics

ISSN: 1559-0275